Molecular apocrine breast cancers are aggressive estrogen receptor negative tumors overexpressing either HER2 or GCDFP15. (Q33739841)

29 July 2017

title

Molecular apocrine breast cancers are aggressive estrogen receptor negative tumors overexpressing either HER2 or GCDFP15. (English)

1 reference

29 July 2017

1 reference

11

Patricia de Cremoux

0 references

Jacqueline Lehmann-Che

1

object named as

Jacqueline Lehmann-Che

0 references

Hugues de Thé

18

object named as

Hugues de Thé

0 references

Anne Janin

16

object named as

Anne Janin

1 reference

29 July 2017

19

Philippe Bertheau

1 reference

29 July 2017

17

Marc Espié

1 reference

29 July 2017

Anne-Sophie Hamy

2

1 reference

29 July 2017

Raphaël Porcher

3

1 reference

29 July 2017

Marc Barritault

4

1 reference

29 July 2017

Fatiha Bouhidel

5

1 reference

29 July 2017

Hanadi Habuellelah

6

1 reference

29 July 2017

Solenne Leman-Detours

7

1 reference

29 July 2017

Anne de Roquancourt

8

1 reference

29 July 2017

Laurence Cahen-Doidy

9

1 reference

29 July 2017

Edwige Bourstyn

10

1 reference

29 July 2017

Patricia de Cremoux

11

1 reference

29 July 2017

Cedric de Bazelaire

12

1 reference

29 July 2017

Marcela Albiter

13

1 reference

29 July 2017

Sylvie Giacchetti

14

1 reference

29 July 2017

Caroline Cuvier

15

1 reference

29 July 2017

publication date

11 May 2013

1 reference

29 July 2017

published in

Breast Cancer Research

1 reference

29 July 2017

volume

15

1 reference

29 July 2017

issue

3

1 reference

29 July 2017

page(s)

R37

1 reference

Cutoff Finder: a comprehensive and straightforward Web application enabling rapid biomarker cutoff optimization

29 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4053236

Runx2 controls a feed-forward loop between androgen and prolactin-induced protein (PIP) in stimulating T47D cell proliferation

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4053236

A refined molecular taxonomy of breast cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4053236

Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4053236

Androgen receptor expression in breast cancer in relation to molecular phenotype: results from the Nurses' Health Study

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4053236

Immunohistochemical and molecular analyses of HER2 status in breast cancers are highly concordant and complementary approaches

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4053236

Androgen receptor expression and breast cancer survival in postmenopausal women

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4053236

ER-α36, a novel isoform of ER-α66, is commonly over-expressed in apocrine and adenoid cystic carcinomas of the breast.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4053236

Molecular apocrine differentiation is a common feature of breast cancer in patients with germline PTEN mutations

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4053236

Expression of FOXA1 and GATA-3 in breast cancer: the prognostic significance in hormone receptor-negative tumours

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4053236

Molecular characterization of apocrine carcinoma of the breast: validation of an apocrine protein signature in a well-defined cohort

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4053236

PIK3CA mutations and BRCA1 expression in breast cancer: potential biomarkers for chemoresistance

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4053236

Refinement of breast cancer classification by molecular characterization of histological special types

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4053236

Androgen receptor expresion in breast cancer: relationship with clinicopathological characteristics of the tumors, prognosis, and expression of metalloproteases and their inhibitors

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4053236

Current issues in ER and HER2 testing by IHC in breast cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4053236

Expression of androgen receptor is negatively regulated by p53.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4053236

The enigmatic nature of apocrine breast lesions

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4053236

An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4053236

Identification of molecular apocrine breast tumours by microarray analysis.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4053236

Androgen receptors frequently are expressed in breast carcinomas: potential relevance to new therapeutic strategies.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4053236

Role of the androgen receptor in human breast cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4053236

A simple p53 functional assay for screening cell lines, blood, and tumors

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4053236

Expression of androgen receptors in primary breast cancer

21 June 2018

1 reference

Field cancerisation and polyclonal p53 mutation in the upper aero- digestive tract

21 January 2018

1 reference

p53 dependent cell-cycle arrest triggered by chemotherapy in xenografted breast tumors.

21 January 2018

1 reference

Androgen receptor in breast cancer: expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation

21 January 2018

1 reference

Androgen receptor levels and association with PIK3CA mutations and prognosis in breast cancer.

21 January 2018

1 reference

Expression and clinical significance of androgen receptor in triple negative breast cancer.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4053236

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4053236

Androgen Receptor Expression in Estrogen Receptor-Negative Breast Cancer Immunohistochemical, Clinical, and Prognostic Associations

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4053236

Evaluation of androgen, estrogen (ER alpha and ER beta), and progesterone receptor expression in human prostate cancer by real-time quantitative reverse transcription-polymerase chain reaction assays

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4053236

Androgen receptor expression in primary breast cancer and its predictive and prognostic value in patients treated with neoadjuvant chemotherapy

30 October 2018

1 reference

12 December 2020

Gross cystic disease fluid protein-15 as a marker for breast cancer: immunohistochemical analysis of 690 human neoplasms and comparison with alpha-lactalbumin

1 reference

12 December 2020

Ductal carcinoma in situ of the breast with apocrine cytology: definition of a borderline category

1 reference

12 December 2020

Intraductal apocrine carcinoma: a clinicopathologic study of 37 cases

1 reference

12 December 2020

Identifiers

DOI

10.1186/BCR3421

1 reference

Dimensions Publication ID

29 July 2017

0 references

1 reference

29 July 2017

1 reference